Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world
Clinical trial NCT05022342 · COMPLETED
Trial details
- NCT number
- NCT05022342
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-10-27
- Primary completion
- 2025-02-11
- Enrollment
- 595
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.